Inclisiran til hyperkolesterolæmi

Nerma Todorovac; Michael Skov Hansen; Frank-Peter Elpert

doi:10.61409/V12230767

Inclisiran til hyperkolesterolæmi

Nerma Todorovac^*, Michael Skov Hansen, Frank-Peter Elpert

^*Kontaktforfatter

Sygehus Sønderjylland

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

Bidragets oversatte titel	Hypercholesterolaemia treated with inclisiran
Originalsprog	Dansk
Artikelnummer	V12230767
Tidsskrift	Ugeskrift for Læger
Vol/bind	186
Udgave nummer	19
ISSN	0041-5782
DOI	https://doi.org/10.61409/V12230767
Status	Udgivet - 30. sep. 2024

Emneord

Adult
Anticholesteremic Agents/therapeutic use
Cholesterol, LDL/blood
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Hyperlipoproteinemia Type II/drug therapy
PCSK9 Inhibitors

Dokumenter og links

10.61409/V12230767Licens: CC BY-NC-ND

Open Access VersionForlagets udgivne version, 49 KBLicens: CC BY-NC-ND

Citationsformater

@article{35d7f6c1e13745d7b60f5e2c3440a928,

title = "Inclisiran til hyperkolesterol{\ae}mi",

abstract = "In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.",

keywords = "Adult, Anticholesteremic Agents/therapeutic use, Cholesterol, LDL/blood, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hyperlipoproteinemia Type II/drug therapy, PCSK9 Inhibitors",

author = "Nerma Todorovac and Hansen, {Michael Skov} and Frank-Peter Elpert",

year = "2024",

month = sep,

day = "30",

doi = "10.61409/V12230767",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "19",

}

TY - JOUR

T1 - Inclisiran til hyperkolesterolæmi

AU - Todorovac, Nerma

AU - Hansen, Michael Skov

AU - Elpert, Frank-Peter

PY - 2024/9/30

Y1 - 2024/9/30

N2 - In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

AB - In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

KW - Adult

KW - Anticholesteremic Agents/therapeutic use

KW - Cholesterol, LDL/blood

KW - Female

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Hyperlipoproteinemia Type II/drug therapy

KW - PCSK9 Inhibitors

U2 - 10.61409/V12230767

DO - 10.61409/V12230767

M3 - Tidsskriftartikel

C2 - 38903035

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 19

M1 - V12230767

ER -

Inclisiran til hyperkolesterolæmi

Abstract

Emneord

Dokumenter og links

Fingeraftryk

Citationsformater